BrainsWay Ltd.
BWAY
NASDAQ·Healthcare·Medical - Specialties·Mkt cap $555.0M
$14.15
▼ -2.48%
P/E
54.42
Mkt Cap
$555.0M
52-Wk Range
$7.14–$17.40
52-Week Range
$7.14 - $17.40
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 78.0% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
No bull reasons captured for this rating yet.
Bear Case
2 risks
- Low volatility (beta 0.2).
- High premium - requires strong execution
Growth
Strong growth ahead
Value
High premium - requires strong execution
Momentum
Stable
+1.9% over 3m
Quality
Excellent
Strong fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying BWAY right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 10, 2026
AUG 12, 2026
Reported EPS of $0.07 vs $0.10 consensus (-30.0% surprise). Revenue of $17.1M vs $16.5M expected (+3.4%).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-30.0%
Revenue trend · last 2Q
—
+38%
Q1 26
Q2 26
$15.5M
$17.4M
Margins · last 2Q
Gross
74.6%
Operating
14.0%
Profit
15.8%
Wall Street consensus
2 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: HC Wainwright · Aug 31, 2026
vs Industry
How BWAY stacks vs Medical - Specialties
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.